H
The Hershey Company
HSY · Consumer Defensive
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
Reese's Is a Fortress Sitting on a Commodity Fault Line
The market is debating GLP-1 drugs as Hershey's existential threat, but the real question is whether West African cocoa supply has structurally broken — because if it has, the exceptional returns-on-capital that justified premium multiples for a decade aren't coming back, and the recovery story baked into current prices evaporates.
Flowly Score
Apr 16 Close
+83%$191.36
Fair Value
$350.00
61
Averageat $191.36
Business Strength6/10
Reese's is a genuine flavor monopoly with century-deep cultural embedding, but the Trust governance structure permanently caps what management can do for public shareholders, and the salty snacks buildout has consumed capital at premium prices without yet proving it belongs in this portfolio. The brand moat is real; the business architecture around it is messier than it looks.
Financial Resilience7/10
The 2025 earnings collapse while OCF barely flinched is one of the clearest demonstrations of cash quality you'll see — non-cash charges gutted reported profits while the actual cash engine ran almost unchanged, confirming the franchise generates real money rather than accounting fiction. Debt is meaningful but well-covered by normalized FCF; the balance sheet is not a source of stress.
Growth & Trajectory5/10
This is a mature business in a saturated geography with a stagnant international segment that has shown zero ability to export brand strength across borders — the salty snacks segment is growing encouragingly, but it's still too small to move the needle on a company this size. The 2026 earnings recovery is credible if cocoa cooperates, but the underlying organic growth engine runs at low single digits in the best of times.
Valuation7/10at $222.78
The optical P/E is meaningless — you're looking at a trough earnings year, not steady-state — and on free cash flow, the business is priced closer to fairly valued or modestly cheap relative to its through-cycle earnings power, with all three DCF scenarios implying meaningful upside from current levels. The catch is that 'through-cycle' is doing a lot of work if cocoa's supply dynamics are structural rather than cyclical.
Risk5/10
Three risks compound in uncomfortable ways: cocoa supply is potentially structural (not just cyclical), private label credibility has risen precisely because Hershey pushed prices high enough to create an umbrella, and the Trust governance means public shareholders cannot force any corrective action if management continues buying trendy adjacencies at full prices. GLP-1 risk is real but specifically overblown for occasion-driven impulse categories — the other three are less appreciated and more durable.
The investment case here is essentially a bet on mean reversion: buy a world-class consumer franchise at trough earnings caused by an external commodity shock, wait for cocoa prices to normalize, and collect the margin recovery plus a business that has quietly demonstrated it can sustain volume through one of the worst cost environments in its history. The FCF yield tells the more honest story than the P/E — the cash engine is still running, the brand hasn't flinched on volume, and management has guided a specific recovery path with pricing already in market. If that recovery materializes, the current price looks reasonable to modestly cheap against normalized earnings power. The direction of travel is incrementally diversifying — salty snacks are showing genuine momentum, and the Q4 organic growth print from that segment was legitimately impressive rather than just acquisitive flattery. Reese's continues to extend successfully across formats without diluting the core identity, which is the hardest trick in branded consumer goods. The longer-term shape of the portfolio gets more defensible each year as salty snacks scale, but it will take another three to five years before that segment is large enough to materially blunt the cocoa exposure that periodically makes this business look like a commodity cyclical wearing a consumer staple costume. The single biggest risk is not GLP-1 medications — it's that cocoa's supply crisis is rooted in aging tree stock, soil exhaustion, and climate variability across a narrow band of West African geography, none of which resolves in an eighteen-month hedge cycle. If input costs normalize, Hershey earns back its exceptional ROIC and the recovery story is real. If they don't, every forward model — including the DCF scenarios that imply substantial upside — is built on an assumption that never arrives, and the brand alone cannot paper over a decade of structural margin compression.